{"filing":{"accession_number":"0001193125-26-341240","cik":"0001479615","ticker":"SLNCF","company_name":"Silence Therapeutics plc","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d162225d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/d162225d8k.htm"},"events":[{"id":26360,"run_id":23951,"accession_number":"0001193125-26-341240","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses Silence Therapeutics' second quarter 2026 financial and business results via a press release issued on August 10, 2026. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheets showing Q2 2026 results (net loss of $12.3 million, R\u0026D expenses of $9.1 million, cash position of $72.1 million) compared to prior-year periods, along with business highlights on clinical programs. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational progress.","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27452,"accession_number":"0001193125-26-341240","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Silence Therapeutics' second quarter 2026 financial and business results via a press release issued on August 10, 2026. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheets showing Q2 2026 results (net loss of $12.3 million, R\u0026D expenses of $9.1 million, cash position of $72.1 million) compared to prior-year periods, along with business highlights on clinical programs. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:21:42.488964+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27452,"accession_number":"0001193125-26-341240","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Silence Therapeutics' second quarter 2026 financial and business results via a press release issued on August 10, 2026. The Item 2.02 disclosure includes condensed consolidated statements of operations and balance sheets showing Q2 2026 results (net loss of $12.3 million, R\u0026D expenses of $9.1 million, cash position of $72.1 million) compared to prior-year periods, along with business highlights on clinical programs. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:21:42.488964+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-10"}]}